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Abstract
Background: P53 mutations are an adverse prognostic factor in esophageal cancer. P53 and KRas mutations are
involved in chemo-radioresistance. Circulating anti-p53 or anti-KRas antibodies are associated with gene mutations.
We studied whether anti-p53 or anti-KRas auto-antibodies were prognostic factors for response to
chemoradiotherapy (CRT) or survival in esophageal carcinoma.
Methods: Serum p53 and KRas antibodies (abs) were measured using an ELISA method in 97 consecutive patients
treated at Saint Louis University Hospital between 1999 and 2002 with CRT for esophageal carcinoma (squamous
cell carcinoma (SCCE) 57 patients, adenocarcinoma (ACE) 27 patients). Patient and tumor characteristics, response
to treatment and the follow-up status of 84 patients were retrospectively collected. The association between
antibodies and patient characteristics was studied. Univariate and multivariate survival analyses were conducted.
Results: Twenty-four patients (28%) had anti-p53 abs. Abs were found predominantly in SCCE (p = 0.003). Anti-p53
abs were associated with a shorter overall survival in the univariate analysis (HR 1.8 [1.03-2.9], p = 0.04). In the
multivariate analysis, independent prognostic factors for overall and progression-free survival were an objective
response to CRT, the CRT strategy (alone or combined with surgery [preoperative]) and anti-p53 abs. None of the
long-term survivors had p53 abs. KRas abs were found in 19 patients (23%, no difference according to the
histological type). There was no significant association between anti-KRas abs and survival neither in the univariate
nor in the multivariate analysis. Neither anti-p53 nor anti-KRas abs were associated with response to CRT.
Conclusions: Anti-p53 abs are an independent prognostic factor for esophageal cancer patients treated with CRT.
Individualized therapeutic approaches should be evaluated in this population.
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Background
Esophageal cancer is a public health issue worldwide. Its
incidence has remained stable over the past thirty years
but its pathologic features have changed dramatically.
The incidence of adenocarcinoma of the esophagus
(ACE) increased 4-fold during this period in the United
States, while that of squamous cell carcinoma (SCCE)
declined by 30%. In contrast, the incidence of SCCE is
highest in Asia, southern and eastern Africa, and north-
ern France, with an annual mortality rate approximating
100 per 100,000 [1]. The risk factors, coexisting condi-
tions, location in the esophagus, natural history and sur-
vival differ between these two histological subtypes. Yet
despite these differences, therapeutic strategies are very
similar and combine surgery, chemotherapy and radio-
therapy [2]. In locally advanced disease, concomitant che-
moradiation (CRT) is the standard treatment [3,4].
Major prognostic factors for esophageal carcinomas
include clinical factors (general condition, initial weight
loss, baseline hemoglobin level), factors related to local
spread (TNM stage [5], lymph node micrometastases, the
ratio between involved and sampled nodes, extracapsular
lymph node involvement), and factors related to the
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evaluated radiographically or endoscopically. These fac-
tors were recently reviewed for ACE [6]. In addition,
molecular pathology has revealed numerous genes and
molecules associated with tumor invasion and metastasis,
some of which exert a prognostic impact per se.Ab e t t e r
knowledge of these factors may not only improve prog-
nostication but may offer new individually tailored thera-
peutic options [7].
Esophageal carcinogenesis is a multi-step process that
transforms normal human cells into tumor cells following
multiple genetic alterations. The circumvention of apopto-
sis appears to play an early and central role in this process.
Mutations of the p53 gene are responsible for reduced
chemo- and radio-induced apoptosis in esophageal cancer
[8]. These mutations are present in around 50% of esopha-
geal cancers, and associated with advanced-stage disease,
poor response to CRT and shorter survival [9,10]. It has
even been suggested that the analysis of p53 polymorph-
isms performed on endoscopic biopsies could identify
patients with Barrett’s esophagus who are at risk of neo-
plastic progression. It could therefore complement the his-
tological examination in deciding the frequency of
endoscopic surveillance in this population.
KRas is a membrane-bound guanosine triphosphate
(GTP)/guanosine diphosphate (GDP)-binding (G) protein
that serves as a “molecular switch,” converting signals
from the cell membrane to the nucleus. These chemical
signals lead to protein synthesis and the regulation of cell
survival, proliferation, and differentiation. It is mutated in
30% of solid tumors, and particularly in 95% of pancreatic
cancers and 50% of colon cancer, but probably only in
less than 10% of esophageal tumors [11]. However, some
reports have suggested much higher levels of mutations
in esophageal carcinomas. In colon cancer, Ras mutations
h a v eb e e ns h o w nt ob ep r e d i c t i v eo fr e s i s t a n c et oa n t i -
EGFR therapy [12].
Gene mutations lead to the synthesis and accumula-
tion of physically altered proteins that are recognized as
« non-self ». The immune system develops antibodies
directed against these aberrant proteins. The detection
of serum antibodies specific for p53 or KRas could be
an easy way to determine an individual’s mutational sta-
tus. The aim of this study was to investigate whether
the level of serum anti-p53 and anti-KRas antibodies
measured prior to CRT is a prognostic marker in eso-
phageal carcinoma patients treated with CRT.
Methods
Patients
We retrospectively reviewed the files of consecutive
patients treated with CRT for esophageal cancer (SCCE
or ACE) at Saint Louis University Hospital (Paris, France)
between December 1999 and December 2002. Data were
collected in 2007 and included: age, sex, performance sta-
tus, tumor stage according to TNM and International
Union against Cancer (UICC) classifications, presence of
dysphagia, weight loss, baseline hemoglobin level, type of
treatment, treatment-related toxicities. Patients had been
followed up every three months after completion of treat-
ment and regularly assessed for the evaluation of
response, local or distant relapse and their vital status.
The vital status had last updated in July 2009. The use of
the patients’ clinical data was approved by the local
research and ethics committee.
Treatment
Treatment consisted of concomitant CRT. Radiation
doses ranging from 40 Gy (peri-operative radiation ther-
apy) to 66 Gy (definitive radiotherapy) were adapted to
each patient’s treatment. Therapy had been delivered
using 3D conformal planning and conventional fractiona-
tion (1.8 Gy per day, five days a week). Unless contraindi-
cated, concomitant chemotherapy had been administered
and consisted of cisplatinum (100 mg.m
-2, day 2) and
5-Flurouracil (1000 mg.m
-2.j
-1, continuous infusion for
3 days), repeated every 4 weeks. Treatment had been fol-
lowed by two to three cycles of Cisplatinum-5FU-based
chemotherapy. When tumors were considered potentially
resectable, tumor response had been evaluated after
40 Gy and operable patients had undergone surgery in
case of a good response. Some patients who had initially
undergone curatively-intended surgery had received
CRT due to the presence of pathologic features carrying
ap o o rp r o g n o s i s .R e s p o n s ea n df o l l o w - u pi n c l u d e d
repeated CT scans and esophagoscopies. Complete
response was defined as a normal CT scan and esophago-
scopy with negative biopsies.
Enzyme Immunoassay for p53 Abs and KRas Abs
Serum anti-p53 and anti-KRas Abs had been measured in
each patient during the week before the initiation of CRT.
For the 6 patients who had received post-operative radio-
therapy, antibodies had been measured after surgery. Anti-
p53 Abs were assessed by ELISA with the anti-p53 ELISA
Kit II (Pharmacell
®, Paris, France) and anti-KRas Abs by a
non-commercialized Pharmacell
® kit. The method used is
an Enzyme Linked Immuno-Sorbent Assay (ELISA) using
microtiter plates coated with recombinant wild-type
human p53 or KRas protein (to detect specific anti-p53 or
anti-KRas antibodies) or with control proteins (to detect
non-specific interactions). A peroxidase-conjugated goat
anti-human IgG binds to auto-antibodies. The specific
protein/auto-antibody/conjugate complexes are revealed
by adding a peroxidase substrate which results in a colori-
metric reaction. Quality procedures included three control
tests for each measurement which was scored as: strong
positive, mild positive and negative. Auto-antibody values
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antibodies, the cut-off value for positivity was set at the
average value among healthy subjects plus three standard
deviations (anti-p53) or plus one standard deviation (anti-
KRas), that is 1.15 U/mL for anti-p53 abs and 0.25 U/smL
anti-KRas abs. These values had previously been deter-
mined by Pharmacell
®. Physicians had been blinded to the
results of anti-p53 and anti-KRas antibody tests during the
treatment period and follow-up, which had been disclosed
by one investigator (MHS) after the end of all treatments.
Statistical analysis
Percentages were compared using the chi-square or Fish-
er’s exact test when appropriate. Quantitative variables
were compared using the Student t test or the Mann-
Whitney rank test. Follow-up was estimated using the
reverse Kaplan-Meier method [13]. Correlation between
p53 and KRas auto-antibody values was estimated using
Pearson’s correlation coefficient. Overall survival and dis-
ease-free survival were estimated using the Kaplan-Meier
method. Progression-free survival was defined as the
time between the beginning of radiotherapy to relapse or
death, whichever occurred first. Survival curves were
compared using the logrank test for the univariate analy-
sis. Variables associated with disease-free or overall survi-
val with a p-value < 0.25 were included in a multivariate
ascending stepwise Cox regression analysis. In the Cox
model, continuous variables were dichotomized. Missing
values were rare (< 1.5%) and were therefore omitted.
Statistical analyses were performed using SAS software,
version 9.1 (SAS Inc, United States). All reported
p-values are two-sided, and p-values lower than 0.05
were considered significant.
Results
Patients and tumors
Between December 1999 and December 2002, 97 patients
were referred for concomitant CRT for esophageal carci-
noma. Thirteen of them had major missing values and
were therefore excluded from the present analysis. The
study population therefore consists of 84 patients. Median
follow-up was 87 months (7.2 years, range: 1-107 months).
Only three patients (4%) had been lost to follow-up during
the first 5 years. Table 1 shows patient and tumor charac-
teristics. The majority of patients were male (75 patients
84%), median age was 60 years (range 38-81 years), in
good general condition (Karnofsky performance status 80-
100: 67 patients 80%). Weight loss was 10% or more in
49% of the patients. Tumor characteristics were as follows:
squamous cell carcinomas (n = 57) and adenocarcinomas
(n = 27). Most of the tumors were considered unresect-
able. Six patients had received post-operative irradiation
due to pathological evidence of involved mediastinal
lymph nodes on the surgical specimen. Sixteen patients
had received pre-operative CRT. For the 17 patients with
metastases, CRT had been administered because disease
was pauci-metastatic, they were in good general condition
and had presented with dysphagia.
Anti-p53 and anti-KRas antibody levels
The median anti-p53 antibody value was 0.25 (range: 0-
159). Anti-p53 Abs were considered positive in 24
patients (29%). All except one patient with positive anti-
p53 Abs had squamous cell carcinoma (23/24). The med-
ian anti-KRas antibody value was 0.16 (range: 0-1.19).
Anti-KRas Abs were considered positive in 19 patients
(23%). There was no correlation between the two serum
auto-antibody levels (Pearson correlation coefficient:
0.05, p-value = 0.6). The 13 excluded patients had the
same levels and frequency of positivity as the study
patients for both auto-antibodies (levels: Mann-Whitney
rank test, p = 0.7 for anti-p53 and p = 0.5 for anti-KRas;
positivity: Chi-square test, p = 0.6 for anti-p53 and p =
0.13 for anti-KRas).
Association between anti-p53 and anti-KRas antibodies
and clinico-pathologic characteristics
The association between antibody positivity and patient
characteristics is presented in Table 2. A younger age and
SCC histology were associated with positive anti-p53 Abs,
whereas no characteristics were associated with anti-KRas
positivity. Neither anti-p53 nor anti-KRas antibodies were
correlated with an objective response to CRT. Response
rates were 67% in anti-p53 negative patients versus 78% in
anti-p53 positive patients (p = 0.4), and 65% in anti-KRas
negative patients versus 82% in anti-KRas positive patients
(p = 0.2).
Survival analysis
Overall 71 patients have died, among which 22 had anti-
p53 antibodies and 16 had anti-KRas antibodies. Median
overall survival for the entire population was 13 months
(95% CI: 719 months. There was a difference according
to the anti-p53 status, in favor of patients with a negative
anti-p53 abs (HR for death [95% CI]: 1.8 [1.03, 2.9], log-
rank p = 0.04). None of the 12 long-term survivors had
p53 antibodies. KRas antibodies were not associated with
overall survival (HR for death [95% CI]: 0.8 [0.5, 1.5], log-
rank p = 0.5). Figures 1 and 2 show Kaplan-Meier curves
for overall survival for anti-p53 and anti-KRas antibodies.
Univariate and multivariate analyses
Table 3 summarizes the results of the univariate and mul-
tivariate analyses. Factors associated with improved overall
survival in the univariate analysis were age > 60 years, a
good performance status, no visceral metastases, an objec-
tive response to CRT, preoperative CRT followed by sur-
gery and no anti-p53 antibodies. After the multivariate
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improved overall survival were: preoperative CRT, an
objective response to CRT and no anti-p53 antibodies.
The progression-free survival analysis showed similar
results, as most relapses were shortly followed by death.
Factors independently associated with better progression-
free survival were: preoperative CRT, an objective
response to CRT and no anti-p53 antibodies, as shown in
Table 4.
Discussion
This retrospective study is the first to evaluate the prog-
nostic significance of anti-p53 and anti-KRas antibodies
in esophageal carcinoma patients treated with CRT.
Anti-p53 antibodies were found in 24 patients (29%),
mainly in SCCE (23/24 patients). Anti-KRas antibodies
were found in 19 patients (23%). It shows that the pre-
sence of serum anti-p53 antibodies measured prior to
CRT is an independent prognostic factor in esophageal
carcinoma treated with CRT. None of the long-term sur-
vivors had anti-p53 antibodies. It is one of the largest stu-
dies to evaluate the prognostic value of anti-p53
antibodies in esophageal cancer. In our series anti-KRas
antibodies had no prognostic impact on esophageal can-
cers. Response to CRT and preoperative CRT were the
other independent prognostic factors, which are even
more strongly correlated with survival. Anti-p53 antibo-
dies were mostly restricted to SCCE, suggesting that they
Table 1 patient and tumor characteristics
Missing values n (%)
Overall population 84 (100)
Gender Female 0 9 (11)
Male 75 (84)
Age (years) < 60 0 42 (50)
≥ 60 42 (50)
Histology ACE 0 27 (32)
SCCE 57 (68)
Karnofsky Performance status ≤ 60 1 10 (12)
70 6 (7)
80 21 (25)
90 25 (30)
100 21 (25)
Dysphagia Solid 0 64 (76)
Liquid 20 (24)
Weight loss ≥ 10% No 2 42 (51)
Yes 40 (49)
Hemoglobin level < 120 g/L Yes 0 57 (68)
No 27 (32)
T Stage 1 0 3 (4)
2 10 (12)
3 59 (70)
4 12 (14)
N Stage 0 0 28 (33)
1 27 (32)
2 29 (35)
M Stage No 0 67 (80)
Yes 17 (20)
Surgery No 0 78 (81)
Yes 16 (19)
Chemoradiotherapy Preoperative 0 16 (19)
Postoperative 6 (7)
Alone 62 (74)
Abbreviations: SCCE, squamous cell carcinoma of the esophagus; ACE, adenocarcinoma of the esophagus
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calculated using the chi-squared test)
Characteristics Anti-p53 antibody Anti-KRas antibody
Negative Positive p-value Negative Positive p-value
Gender Female 6 (10) 3 (12.5) 0.7 9 (14) 0 (0) 0.09
Male 54 (90) 21 (87.5) 56 (86) 19 (100)
Age (years) < 60 25 (42) 17 (71) 0.02 32 (49) 10 (53) 0.8
≥ 60 35 (58) 7 (29) 33(51) 9 (47)
Histology ACE 25 (42) 2 (8) 0.003 24 (37) 3 (16) 0.08
SCCE 35 (58) 22 (91) 41 (63) 16 (84)
Karnofsky Performance status ≤ 80 23 (38) 14 (61) 0.06 27 (42) 10 (53) 0.4
90-100 37 (62) 9 (39) 37 (58) 9 (47)
Weight loss ≥ 10%% No 33 (57) 9 (37.5) 0.1 34 (53) 8 (44) 0.5
Yes 25 (43) 15 (62.5) 30 (47) 10 (56)
Dysphagia Solid 49 (82) 15 (62.5) 0.06 48 (74) 16 (84) 0.4
Liquid 11 (18) 9 (32.5) 17 (26) 3 (16)
Hemoglobin level < 120 g/L Yes 40 (37) 17 (29) 0.5 20 (31) 9 (47) 0.2
No 20 (63) 7 (71) 45 (69) 10 (53)
T Stage 1-2 12 (20) 1 (4) 0.07 12 (18) 1 (5) 0.2
3-4 48 (80) 23 (96) 53 (82) 18 (95)
N Stage 0 19 (32) 9 (37.5) 0.6 22 (34) 6 (32) 0.9
1-2 41 (68) 15 (62.5) 42 (66) 16 (68)
M Stage Non 49 (82) 18 (75) 0.5 52 (80) 15 (79) 0.9
Oui 11 (18) 6 (25) 13 (20) 4 (21)
Abbreviations: SCCE, squamous cell carcinoma of the esophagus; ACE, adenocarcinoma of the esophagus
4 8 12 12 13 14 17 31 60
1 12 24
0%
20%
40%
60%
80%
100%
0 1 22 43 64 86 07 28 49 6
Months after radiotherapy
Anti-p53 negative
Anti-p53 positive
At risk
logrank: p = 0,04
Figure 1 Kaplan-Meier curve of overall survival according to anti-p53 antibody status.
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no correlation between anti-p53 antibodies and response
to CRT. Thus the prognostic impact of anti-p53 abs is
independent of the initial response to CRT, but most
probably stems from a lower rate of relapse in anti-p53-
negative tumors.
According to our study, anti-KRas antibodies have no
prognostic value in esophageal carcinoma, which could
be linked to the low percentage of ras mutations in this
cancer. However, their prognostic value should be evalu-
ated in other cancers where ras mutations are more
frequent.
Figure 2 Kaplan-Meier curve of overall survival according to anti-KRas antibody status.
Table 3 Univariate analysis of prognostic factors for overall survival
Univariate analysis (Logrank) Multivariate analysis (Cox)
Characteristics (reference) HR 95% CI P-value HR 95% CI P-value
Patient Characteristics
Gender (male vs female) 1.3 0.6-2.7 0.6 - - -
Age (≥ 60 vs < 60 years) 0.5 0.3-0.8 0.005 - - -
Pretreatment hemoglobin level (< 120 vs ≥ 120 g/L) 0.97 0.6-1.6 0.9 - - -
Initial weight loss (≥ 10% vs < 10%) 1.4 0.8-2.2 0.2 1.5 0.9-2.7 0.1
Dysphagia (mild vs liquid) 1.3 0.8-2.3 0.3 - - -
Karnofsky Performance status (≤ 80 vs 90-100) 2 1.25-3.3 0.008 1.7 0.99-3 0.06
Tumor Characteristics
Histology (SCCE vs ACE) 1.15 0.7-1.9 0.6 - - -
T Stage (3-4 vs 1-2) 1.1 0.6-2 0.8 - - -
N Stage (1 vs 0) 1.4 0.9-2.4 0.15 - - -
M stage (1 vs 0) 1.8 1.01-3.1 0.04 - - -
Treatment-related Characteristics
Objective response to CRT (no vs yes) 3.3 1.9-5.9 < 0.0001 3.3 1.6-6.8 < 0.001
Definitive CRT vs Preoperative CRT 2.5 1.4-5.0 0.005 7.1 3.6-13.1 < 0.0001
Antibodies
Anti-p53 (positive vs negative) 1.8 1.03-2.9 0.04 2 1.05-2.8 0.04
Anti-Ras (positive vs negative) 0.8 0.5-1.5 0.5 - - -
Abbreviations: ACE, adenocarcinoma of the esophagus; CI, confidence interval; CRT, chemoradiotherapy; HR, hazard ratio; SCCE, squamous cell carcinoma of the
esophagus
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rospective and monocentric nature. This series appears
heterogeneous because various locoregional treatments
were administered. In addition, there may be a selection
bias due to the exclusion of 13 patients because of missing
patient information. However, such a bias is less likely
because auto-antibody values were similar between the
excluded and included populations. Moreover, all known
clinical prognostic factors [6] were collected for the study
population, thus minimizing confusion bias. As recom-
mended in biomarker studies, the treating physicians were
blinded to the auto-antibody results, which therefore had
no incidence on the therapeutic strategy. As with any ret-
rospective study, this series needs to be confirmed by
other retrospective and if possible prospective studies.
Table 5 shows the prognostic value of p53 mutations for
overall survival [8-10,14-16], event-free survival [9,17] and
response rate [8,9,18] in other reports on esophageal can-
cer. Those values are consistent with the findings reported
here. They are also consistent with series reported con-
cerning other cancers [for review see [19].
The methods used to determine the p53 or k-ras muta-
tional status merit discussion. Indeed, the question is
whether anti-p53 antibodies are a reliable yardstick for the
p53 mutational status. Many studies previously demon-
strated that p53 antibodies were restricted to cancer
patients bearing p53 mutations [22,23]. These antibodies
have a high specificity, but lack sensitivity. Indeed, they
have the same drawbacks as immunohistochemistry,
because they are absent in patients in whom p53 muta-
tions result in the absence of p53 protein synthesis and
accumulation [24]. Other met h o d ss u c ha ss e q u e n c i n g ,
immunohistochemical analysis and functional assays have
been developed to determine the p53 status and have been
applied to esophageal carcinomas (Table 5). Nowadays
DNA chips are being used increasingly to investigate the
tumor genetic status. As they allow many genes to be stu-
died simultaneously, we may no longer need to use tests
like anti-p53 antibodies. Notwithstanding, measuring
serum antibodies with the ELISA method is easy and
reproducible. This could be a simple way to determine the
p53 status, with quantitative information. Indeed, the peri-
operative variations in serum p53 antibodies have been
shown to predict overall survival [16]. P53 antibody titers
could be used for the follow-up of patients with initially
elevated p53 antibodies. As p53 mutated tumors have a
worse prognosis and different response to treatment than
p53 wild type tumors, monitoring the p53 tumor status
and function is central in the context of individualized
medicine.
Conclusions
In brief, our study shows that anti-p53 antibodies are an
independent prognostic marker in esophageal cancer
patients. The antibodies are mostly restricted to squamous
cell carcinoma. This series is consistent with most pub-
lished series studying the p53 status in esophageal cancer,
suggesting that the p53 status should be monitored in
Table 4 Univariate analysis of prognostic factors for progression-free survival
Univariate analysis(Logrank) Multivariate analysis (Cox)
Characteristics (reference) HR 95% CI P- value HR 95% CI P-value
Patient Characteristics
Gender (male vs female) 1.4 0.6-3.5 0.4 - - -
Age (> 60 vs < 60 years) 0.5 0.3-0.8 0.02 0.6 0.3-1.1 0.1
Pretreatment hemoglobin level (< 120 vs > 120 g/L) 1 0.6-1.6 0.9 - - -
Initial weight loss (> 10% vs < 10%) 1.3 0.8-2.1 0.3 - - -
Dysphagia (mild vs liquid) 1.2 0.7-2.1 0.4 - - -
Karnofsky Performance status (< 80 vs 90-100) 0.6 0.3-0.9 0.01 - - -
Tumor Characteristics
Histology (SCCE vs ACE) 1 0.6-1.7 0.9 - - -
T Stage (3-4 vs 1-2) 1 0.5-1.8 0.9 - - -
N Stage (1 vs 0) 1.3 0.8-2 0.4 - - -
M stage (1 vs 0) 1.8 1-3.1 < 0.05 1.7 0.9-3.4 0.1
Treatment-related Characteristics
Objective response to CRT (no vs yes) 3.3 2.0-5.0 < 0.0001 4.8 2.4-9.4 < 0.0001
Definitive CRT vs Preoperative CRT 2.5 1.25-5.0 0.01 2.4 1.2-4.8 < 0.02
Antibodies
Anti-p53 (positive vs negative) 1.8 1.05-2.9 0.03 2 1-3.9 0.04
Anti-Ras (positive vs negative) 0.8 0.5-1.4 0.5 - - -
Abbreviations: ACE, adenocarcinoma of the esophagus; CI, confidence interval; CRT, chemoradiotherapy; HR, hazard ratio; SCCE, squamous cell carcinoma of the
esophagus
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ter define the prognostic implications of p53 mutations,
their distribution amongst the histological subtypes of eso-
phageal cancer, and whether treatments should be adapted
to the tumor p53 status.
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